Introduction
Delayed arterial healing with poor strut coverage has been identified as the major substrate responsible for late and very late stent thrombosis (LST/VLST) following 1 st -generation stainless steel sirolimus-eluting stent (SES) and paclitaxel-eluting stent (PES) placement. 1, 2 Human autopsy studies have demonstrated that 1 st -generation drug-eluting stents (DES) placed for "offlabel" indications exhibit further delayed healing as compared to those implanted for "on-label"
indications. 3, 4 SES and PES show divergent mechanisms of LST/VLST: hypersensitivity reaction with diffuse extensive inflammation in the former versus malapposition with excessive fibrin deposition in the latter. 4 In addition, in-stent neoatherosclerosis and stent fracture have emerged as other important contributing factors for late adverse events including LST/VLST and late target-lesion revascularization (TLR) following SES and PES placement. Neoatherosclerosis develops rapidly and more frequently within 1 st -generation DES as compared to bare metal stent (BMS). 5 The incidence of stent fracture in 1 st -generation DES has been reported to vary from 1.3 to 8.4% in clinical studies. 6, 7 However, in autopsy study where high-contrast film-based radiography was used, the prevalence of fracture was 29% in the 1 st -generation DES where grade V fracture was identified in 5% of the lesions and was associated with increased risk of restenosis and thrombosis. de eve ve velo lo lop ps ps r r rap ap api i idly y a a and nd n more frequently within 1 st -g -g -gen n neration DES as as a com om mp pa pared to bare metal stent lower incidence of stent thrombosis in CoCr-EES versus SES. 12, 13 While better safety profile of CoCr-EES versus SES has not been consistently reported in head-to-head randomized trials, recent large-scale registry data 14 and meta-analysis of randomized trials 15, 16 have revealed that
CoCr-EES shows substantially less stent thrombosis as compared to SES and PES.
Nevertheless, vascular responses to CoCr-EES versus SES and PES need further clarification since pathology of CoCr-EES has not been reported in humans. Although clinical studies utilizing optical coherence tomography have reported better strut coverage in CoCr-EES versus SES and PES at 6 to 9 months following stent placement, 17 detailed assessment of vascular response to CoCr-EES including the degree of inflammation, fibrin deposition, and strut coverage in relation to underlying plaque morphology, along with the mechanism(s) of stent thrombosis, can only be determined by histopathologic studies. Moreover, the prevalence and characteristics of neoatherosclerosis as well as the impact of stent fracture on adverse pathologic outcomes in CoCr-EES remain to be elucidated. In the current study, we investigated pathologic response to CoCr-EES as compared to SES and PES in human coronary arteries using a registry database of autopsy cases.
Methods

Study population
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Vascular, Santa Clara, CA; or PROMUS, Boston Scientific]), from 220 autopsy cases. Of these, all available CoCr-EES (n=46 lesions) were included in the current study and the maximum duration of implant was 3 years (median=200 days, 25th to 75th percentiles [121 -360] were considered to be separate lesions. 1 All available clinical records were reviewed for patient history, duration of implant, risk factors, and medications. "Off-label" indication was defined as stents deployed for acute myocardial infarction (AMI), bifurcation lesion, left main coronary artery, bypass graft, restenosis, chronic total occlusion, or lesion length >30 mm. 18 Cause of death was reported as stent-related death, nonstent-related cardiac death, and noncardiac death, as described previously.
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Histologic preparation
Epicardial coronary arteries were dissected from the heart and radiographed using high-contrast film-based radiography. Stented arteries were submitted for plastic embedding in methylmethacrylate. The entire stent was then sawed serially at 2 to 3 mm intervals. Histologic EES [>30 days, 3 years]) were evaluated in the current study. The current study dy d did id id n n not ot ot i i inc nc nclu lude de esions with platinum-chromium (PtCr) paclitaxel-eluting TAXUS Element stent (Boston Sc Scie ie ient nt ntif if ifi i ic) ) ) or or o PtC tC Cr r r ev e erolimus-eluting PROMUS S S E El lement stent (B B Bosto ton n n S Scientific). Overlapping or c c co onsecutive ely ly im mp mpla lant nt ted d ed s s ste te tent nts w w wer ere e e t tr reat t ted d d as 1 les sio io ion, n, , w w wh hi hile le e s st tents ts s in nc nclu lu ud di ding ng a a a g g gap ap p o o of f f >5 >5 5 m m mm sections were cut at 6 μm and stained with hematoxylin and eosin (H&E) along with Movat pentachrome, as previously described.
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Pathologic assessment and morphometric analysis
The severity of calcification in the stented lesion was assessed based on the radiographs as previously described: none, mild, moderate, and severe. 8 Stent fracture was identified by assessment of high-contrast film-based radiographs and classified as grade I to V, where grade V fracture was defined as multiple strut fractures with acquired transection with gap in the stent body, as previously described. 8 Acute stent thrombosis was defined as a platelet-rich thrombus occupying >30% of the cross-sectional area of the lumen while stent restenosis was defined as >75% cross sectional area narrowing by neointimal formation within the stented area, with or without atherosclerosis. 1, 4 Timing of the stent thrombosis was classified based on the Academic
Research Consortium definition as LST (31 days to 1 year) or VLST (>1 year). The underlying plaque morphology (outside stent struts) was classified using traditional definitions of pathologic intimal thickening, fibroatheroma, thin-cap fibroatheroma, plaque rupture, and fibrocalcific plaque. 19 Newly formed atherosclerotic changes within the stented segment (neoatherosclerosis)
were classified into peri-strut foamy macrophage clusters, fibroatheroma, thin-cap fibroatheroma, and in-stent plaque rupture, as defined previously. 5 Diffuse neoatherosclerosis was characterized by involvement of >50% of stent length by either foamy macrophages, fibroatheroma, thin-cap fibroatheroma, or rupture, and 50% involvement was defined as focal neoatherosclerosis.
Morphometric analysis and histologic assessment of coronary sections were performed as previously described. 4 Morphometric measurements (IPLab, Scanalytics, Rockville, MD)
included external elastic lamina, stent, and lumen areas, as well as the thickness above each strut.
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Re Rese se sear ar arch ch ch C C Con on nso ort rt rtiu iu ium m definition as LST (31 days ys s to to 1 year) or VL L LST S ( (>1 >1 >1 year). The underlying pl laue u morph hol ol lo og ogy y (o (o (out ut tsi si side de de s st te tent nt s st t tru rut ts) ) ) wa as c clas ssi sif fied d d u u usi sing ng ng t tra ra adi dit tio iona na al de defi fi fini n niti tion on ns s of of f pat at atho ho holo o ogic n nti ti tima ma mal l l th thic ic cke ke keni nin ng ng, , , fi fib b bro oa oath ther er rom om ma a, a, t t th hi hin n-n-ca ca cap p p f fibr br broa oa ath h her erom om oma, a, a, p pla la laqu qu que e ru ru rupt pt tur ure, e, a a and nd nd f fib ib bro ro roca a alc lci if ific ic plaque. 19 19 19 New ew wly ly ly f f for or orme me med d d at t the he hero r r sc sc scle le l ro ro rotic c c ch ch chan an ange ge ges s wi wi w th th thin in t t the he he s s ste te ent nt nted ed e s s seg eg egme me ment nt nt ( (ne ne neoa oa oath th her er e osclerosis) ) n n Uncovered struts were identified by the presence of platelet and/or fibrin thrombus or bare struts with absence of neointima, and reported as ratio of uncovered-to-total stent struts per section. 1 Strut coverage was also evaluated based on the presence or absence of >30% uncovered struts in at least one cross section, which has been shown to be a strong predictor of LST/VLST. 1 The degree of fibrin deposition was evaluated as the percentage of struts with fibrin, while the severity of inflammation was assessed based on a grading scale of 0 to 4 (score 0 = <25% struts with fewer than 10 inflammatory cells, score 1 = up to 25% struts with greater than 10 inflammatory cells, score 2 = 25-50% struts with greater than 10 inflammatory cells, score 3 = >50% struts with greater than 10 inflammatory cells, and score 4 = two or more strut-associated granulomatous inflammatory reactions). Hypersensitivity reaction was defined as diffuse circumferential inflammation predominantly consisting of T-lymphocytes and eosinophils. The percentage of stent struts with giant cells and maximum number of eosinophils around each strut were also evaluated. 4 In select cases, Luna's staining method was used to confirm the infiltration of eosinophils. Immunohistochemical staining was performed in select cases using standard avidin-biotin techniques as previously described. 5 Immunohistochemistry was carried out for the identification of macrophages using an anti-CD68 antibody (dilution 1:400, Dako, Carpinteria, CA), T-lymphocytes by an anti-CD45RO antibody (dilution 1:100, Dako), and B-lymphocytes using an anti-CD20 antibody (dilution 1:50, Dako).
Statistical analysis
Results for continuous variables with normal distribution were expressed as mean ± SD.
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Results
Patient and lesion characteristics and outcome of DES
There were no differences in clinical characteristics between CoCr-EES and 1 st -generation DES ( CoCr-EES were identified as uncovered struts associated with overlapping stents and neointimal erosion with restenosis, respectively (Figure 2) . The prevalence of restenosis observed for CoCr-EES (17%) did not differ significantly from SES (14%) and PES (12%).
Morphometric analysis
Morphometric analysis was performed on a total of 1357 histologic sections (SES=479, PES=578, CoCr-EES=300) with 14,456 struts (SES=4546, PES=6037, CoCr-EES=3873) ( Table   2 ). Areas of external elastic lamina, stents, and underlying plaques were observed to be smaller SES, PES, and CoCr-EES implanted for stable coronary artery disease (CAD) an n nd d d fo fo f r r ac ac acut ut ute e e coronary syndromes (ACS) are shown in Figure 1 .
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The e e ob ob o se erv rv rved e frequency of LST and VLST ST ST w within the stud d dy y po opu pu pula l tion was less in CoCr-E EES S S (4%) as co comp mp mpar red ed e t t to o SE SE SES S S (2 (21% 1% 1%, p= p= =0.0 02 29 9 9) and nd nd PES ES ES ( (2 2 26% %, %, p p p= =0 =0.0 0 008 0 0 ) ) (a (a aft f fte er er a adj dj dju us ustm tm men en ent t fo fo f r r r du dura ra rati ti tion on o o of f f im im impl plan an ant) t) ( ( (Ta Ta abl ble e 1) 1) 1). Th Th Ther er ere e we we were re re t t tw wo o o le les s sio o ons s s wi wi with th th C C CoC oC oCr-r-EE EE EES S S sh sh how ow win in ng g g LS LS LST, T, a a and nd d n no o o VLST was o obs bs bser er e ve ve ved d d in n n C C CoC oC Cr-r-r EE EE ES. S. S B B Bot t th h h of of of t t the he he l les es e io io ions ns n w w wit it ith h h LS LS LST T T in n n t t the he he C C CoC oC oCr-r-EE EE EES S S gr gr grou o p had The maximum neointimal thickness and the prevalence of DES with >30% uncovered struts in CoCr-EES versus SES or PES were further compared based on stratified duration of implant ( Figure 3 ). All DES showed progressive increase in the maximum neointimal thickness and gradual decrease in the prevalence of DES lesions with >30% uncovered struts as the duration of implant increased. The maximum neointimal thickness did not differ significantly between the groups within each period of the duration of implant. In contrast, the prevalence of lesions with >30% uncovered struts in CoCr-EES was lower than that in SES and PES at each duration of implant where the differences between the groups were statistically significant for 3 to 9 months (for CoCr-EES versus PES) and 9 to 36 months (for CoCr-EES versus both SES and PES) (Figure 3 ).
Further subgroup analysis demonstrated that the superiority of CoCr-EES over SES and PES in terms of lower prevalence of >30% uncovered struts was consistently observed irrespective of age, gender, indications for stenting (stable CAD versus ACS, and "on-versus off-label"), and lesion characteristics including lesion location, stent length, stent diameter, indications was less as compared to that for "on-label" indications in all DES. However, CoCr-EES as compared to SES and PES showed greater strut coverage for both "on-and off-label"
indications.
Stent struts with fibrin deposition were significantly less in Eosinophil infiltration and giant cell reaction were also significantly less in CoCr-EES as compared to SES; however, CoCr-EES showed greater giant cell reaction as compared to PES.
The observed frequency of malapposition was lower in CoCr-EES (4%) as compared to SES (16%) and PES (18%), although the differences were not statistically significant. No hypersensitivity reaction was observed in CoCr-EES, whereas 8% of SES (6 of 73) showed hypersensitivity. One patient had received two SES and one CoCr-EES implants: both of the SES showed diffuse hypersensitivity reaction and one of them had occlusive thrombus, while the CoCr-EES showed only focal inflammation with eosinophils and T-lymphocytes without hypersensitivity reaction ( Figure 5A ). A total of 4 lesions (8.7%) had focal eosinophil infiltration (>10 per strut) with T-lymphocytes in CoCr-EES ( Figure 5B ).
Prevalence and characteristics of neoatherosclerosis
The overall prevalence of neoatherosclerosis following CoCr-EES implantation in native coronary arteries was 29%, which did not differ significantly from SES (35%) and PES (19%) ( Table 2 ). There was no significant difference in the observed frequency of each characteristic of neoatherosclerosis (foamy macrophage clusters, fibroatheroma, and thin-cap fibroatheroma or in- .26) and PE PE PES S (2 (2 (2.4 .4 . %, %, % p p=0 =0 0.9 .9 . 6) 6) 6). . Mo Mo M re re eov ov over er er, , th th ther er ere e wa wa w s no no no s s sig ig igni ni nifi fi fica ca ant nt n d d dif if iffe fe fere re renc nc ce e e in in in f f fra ra racture-
The principal findings of the current autopsy study are: (1) CoCr-EES showed a lower frequency of LST/VLST with less uncovered struts, less inflammation (with no hypersensitivity), and less fibrin deposition as compared to SES and PES in humans; (2) greater strut coverage in CoCr-EES versus SES and PES was consistently identified irrespective of lesion characteristics and indications for stenting; (3) neointimal thickness in CoCr-EES was similar to SES and PES, and progressively increased with time; (4) CoCr-EES showed presence of neoatherosclerosis, the frequency of which was comparable to SES and PES; and (5) overall stent fracture was less frequent in CoCr-EES versus SES, whereas the prevalence of fracture-related adverse events (restenosis and thrombosis) in CoCr-EES did not differ from SES and PES. To our knowledge, the current study represents the first report of the pathology of CoCr-EES as compared to SES and PES in human coronary arteries.
Poor strut coverage has been shown to be the best predictor of LST/VLST following 1 stgeneration DES placement. 1 In this regard, fewer uncovered struts in CoCr-EES likely contributed to a lower frequency of LST/VLST, which could be associated with improved DES components. In vivo and ex vivo experimental studies have shown that thin stent struts are associated with less flow disturbance, greater endothelial cell coverage, and less thrombogenicity, as compared to thick stent strut. 20, 21 Fluorinated copolymer of CoCr-EES consists of vinylidene fluoride and hexafluoropropylene, which is clinically used for permanent surgical sutures and thus proven to be biocompatible. 9 In addition, fluorinated copolymer coating has been shown in ex vivo studies to be thromboresistant as compared to CoCr BMS (Multi-Link Vision). Hypersensitivity vasculitis with eosinophils and T-lymphocytes has been shown to be an important pathologic etiology of LST/VLST in SES, which is likely a response to the polymer rather than the drug. 4 Reduced inflammation without hypersensitivity vasculitis in CoCr-EES could be attributed to greater biocompatibility of the fluorinated copolymer, although limited sample size in the current study must be taken into consideration. In porcine coronary model, CoCr-EES showed similar or even greater inflammation as compared to SES at 28 and 90 days following stent placement; however, decreasing inflammatory response was observed in CoCr-EES over time while SES showed escalating amount of inflammation up to 1 year. 27 On the other hand, malapposition with excessive fibrin deposition is known to be associated with PES thrombosis. 4 Considering that a cytotoxic drug paclitaxel showed a dose-dependent increase in fibrin deposition in preclinical animal models, 28 reduced fibrin deposition in CoCr-EES might be partly attributable to optimal dose of a cytostatic drug everolimus and its better release kinetics.
Clinical imaging studies have demonstrated that VLST following 1 st -generation DES placement DES for "off-label" indications.
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CoCr-EES failed to show a reduction in the prevalence of neoatherosclerosis versus SES and PES in this study population, although the morphology of neoatherosclerosis in CoCr-EES was characterized mostly by foamy macrophage infiltration in comparison to SES. It has been reported that 1 st -generation DES develop neoatherosclerosis rapidly and more frequently as compared to BMS, where no neoatherosclerosis was identified in BMS implanted for 2 years.
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It is believed that accelerated neoatherosclerosis in 1 st -generation DES might be secondary to incompetent re-generated endothelium with poor cell-to-cell junctions that characterize impaired endothelial barrier function. CoCr-EES observed in the current study indicate that careful long-term follow-up is still required even after CoCr-EES placement, and further improvement in stent technologies are needed to overcome these issues.
Study Limitations
There is an inherent bias in studies involving an autopsy population with a relatively greater number of patients dying from DES complications as compared to clinical studies which have a defined large population of living patients. Nevertheless, clinical studies lack the precise nature of the complication as resolution of imaging modalities are limited and the nature of the defect at he FDA.
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1 † Using ordered logistic regression on 16 cuts in counts dominated by 0, because no transformation justified linear regression. This retained robust variance estimates and correction for intra-class correlations among lesions.
‡ Using Poisson regression for these counts data. § Tabular Fisher's exact test substituted for regression, because regression fails where CoCr-EES perfectly predicts absence of hypersensitivity reaction and TCFA / in-stent plaque rupture vs. SES. Evaluated on DES implanted in native coronary arteries. ¶ Using multinomial logistic regression with None as the reference. Abbreviations as in Table 1 . A A l lo ow w-p -pow ow ower er i ima ma mage ge g (C C C) ) ) s sho ho hows n n-s -s ste te ent nt n r res es ste te teno nos si is wi wit th h l l lum umin in na al l l th th thro ro romb mb bus us us ( ( (T Th Thr) r) r) w w whe he ere e e ne ne eoi oi oint ntim im ima a a is is s f f foc oc cal l lly ly d d dis is sse se s ct ct cted ed ed d d due ue ue t to o t th the e e balloon angi giop op opla la last st ty y y wi wi with th h o o ove ve verl r r yi yi ying ng n n n non n n-o -o -occ cc cclu lu lusi si sive ve ve t t thr hr hrom om mbu bu bus. s. s. A A A h h hig i i h-h-h-po po powe we wer r r im im imag ag age e e (D (D (D) Table 3 ). Radiograph hows a patent lumen with moderate neointimal growth (50% cross-sectional are ea a na n n r rr rrow ow owin in ing) g) g . . 
